Search
ROG.VX: Roche's anti PD-L1 must be restricted in 2nd line lung unlike competitor, without superi
Roche's MPDL worse than chemo in 2nd line PD-L1-ve lung, but doesn't have better data in PDL1 +ves either
Much excitement has been caused by Roche's immuno oncology anti PD-L1 drug MPDL3280A in lung cancer. However we examine the data from all the competitors and find the data uncompelling versus the competition.
